2. Academic Validation
  3. Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent

Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent

  • mBio. 2019 Mar 12;10(2):e00159-19. doi: 10.1128/mBio.00159-19.
Melissa D Barnes # 1 2,  Vijay Kumar # 3,  Christopher R Bethel 1,  Samir H Moussa 4,  John O'Donnell 4,  Joseph D Rutter 1,  Caryn E Good 5,  Kristine M Hujer 1 2,  Andrea M Hujer 1 2,  Steve H Marshall 1,  Barry N Kreiswirth 6,  Sandra S Richter 7,  Philip N Rather 8 9,  Michael R Jacobs 2 5,  Krisztina M Papp-Wallace 1 2 3,  Focco van den Akker 10,  Robert A Bonomo 11 2 3 12 13 14 15 16
Affiliations

Affiliations

  • 1 Louis Stokes Cleveland Veterans Affairs Medical Center Research Service, Cleveland, Ohio, USA.
  • 2 Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
  • 3 Department of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA.
  • 4 Entasis Therapeutics, Waltham, Massachusetts, USA.
  • 5 Department of Pathology, University Hospitals, Cleveland Medical Center, Cleveland, Ohio, USA.
  • 6 Public Health Research Institute Tuberculosis Center, New Jersey Medical School, Rutgers University, Newark, New Jersey, USA.
  • 7 Cleveland Clinic Foundation, Cleveland, Ohio, USA.
  • 8 Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.
  • 9 Research Service, Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA.
  • 10 Department of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA fxv5@case.edu robert.bonomo@va.gov.
  • 11 Louis Stokes Cleveland Veterans Affairs Medical Center Research Service, Cleveland, Ohio, USA fxv5@case.edu robert.bonomo@va.gov.
  • 12 Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, Ohio, USA.
  • 13 Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio, USA.
  • 14 Department of Proteomics and Bioinformatics, Case Western Reserve University, Cleveland, Ohio, USA.
  • 15 CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, Ohio, USA.
  • 16 Geriatric Research Education and Clinical Centers (GRECC), Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA.
  • # Contributed equally.
PMID: 30862744 DOI: 10.1128/mBio.00159-19
Abstract

Multidrug-resistant (MDR) Acinetobacter spp. poses a significant therapeutic challenge in part due to the presence of chromosomally encoded β-lactamases, including class C Acinetobacter-derived cephalosporinases (ADC) and class D oxacillinases (OXA), as well as plasmid-mediated class A β-lactamases. Importantly, OXA-like β-lactamases represent a gap in the spectrum of inhibition by recently approved β-lactamase inhibitors such as avibactam and vaborbactam. ETX2514 is a novel, rationally designed, diazabicyclooctenone inhibitor that effectively targets class A, C, and D β-lactamases. We show that addition of ETX2514 significantly increased the susceptibility of clinical Acinetobacterbaumannii isolates to sulbactam. AdeB and AdeJ were identified to be key efflux constituents for ETX2514 in A. baumannii The combination of sulbactam and ETX2514 was efficacious against A. baumannii carrying blaTEM-1, blaADC-82, blaOXA-23, and blaOXA-66 in a neutropenic murine thigh Infection model. We also show that, in vitro, ETX2514 inhibited ADC-7 (k2/Ki 1.0 ± 0.1 × 106 M-1 s-1) and OXA-58 (k2/Ki 2.5 ± 0.3 × 105 M-1 s-1). Cocrystallization of ETX2514 with OXA-24/40 revealed hydrogen bonding interactions between ETX2514 and residues R261, S219, and S128 of OXA-24/40 in addition to a chloride ion occupied in the active site. Further, the C3 methyl group of ETX2514 shifts the position of M223. In conclusion, the sulbactam-ETX2514 combination possesses a broadened inhibitory range to include class D β-lactamases as well as class A and C β-lactamases and is a promising therapeutic candidate for infections caused by MDR Acinetobacter spp.IMPORTANCE The number and diversity of β-lactamases are steadily increasing. The emergence of β-lactamases that hydrolyze carbapenems poses a significant threat to our Antibiotic armamentarium. The explosion of OXA Enzymes that are carbapenem hydrolyzers is a major challenge (carbapenem-hydrolyzing class D [CHD]). An urgent need exists to discover β-lactamase inhibitors with class D activity. The sulbactam-ETX2514 combination demonstrates the potential to become a treatment regimen of choice for Acinetobacter spp. producing class D β-lactamases.

Keywords

Acinetobacter; DBO; ETX2514; beta-lactamases; beta-lactams; diazabicyclooctanone; diazabicyclooctenone; sulbactam; β-lactamase inhibitor.

Figures
Products